The latest update is out from Trajan Group Holdings Ltd ( (AU:TRJ) ).
Trajan Group Holdings Limited reported a record net revenue of $81.0 million for the first half of FY25, marking a 6% increase from the previous year. The company saw significant growth in its Capital Equipment and Components & Consumables segments, driven by strong demand in the pharmaceutical sector and a broadening mix of application areas. Despite some challenges in the pharmaceutical industry and a discontinued biotech syringe product, the company maintained its full-year guidance and reduced net debt by $6.2 million. Trajan’s strategic focus on emerging product lines and integration of acquired businesses like Axel Semrau and LEAP Technologies has positioned it well for future growth.
More about Trajan Group Holdings Ltd
Trajan Group Holdings Limited is a global analytical science and device company. It operates primarily in the Components & Consumables, Capital Equipment, and Disruptive Technologies segments, focusing on providing solutions for pharmaceutical, clinical, and environmental applications.
YTD Price Performance: -29.20%
Average Trading Volume: 20,526
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$121.9M
See more insights into TRJ stock on TipRanks’ Stock Analysis page.